Daewon Pharmaceutical Co., Ltd.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Public
- Established
- 1958-01-07
- Employees
- 1.2K
- Market Cap
- -
- Website
- http://www.daewonpharm.com
Clinical Trials
37
Active:0
Completed:30
Trial Phases
5 Phases
Phase 1:12
Phase 2:3
Phase 3:15
+2 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (36 trials with phase data)• Click on a phase to view related trials
Phase 3
15 (41.7%)Phase 1
12 (33.3%)Phase 4
4 (11.1%)Phase 2
3 (8.3%)Not Applicable
2 (5.6%)A Study to Evaluate the Efficacy and Safety of DW5121 Compared to DW51211 and DW51212
Not Applicable
Completed
- Conditions
- Acute Bronchitis
- Interventions
- Drug: DW5121Drug: DW51211Drug: DW51212
- First Posted Date
- 2025-07-30
- Last Posted Date
- 2025-07-30
- Lead Sponsor
- Daewon Pharmaceutical Co., Ltd.
- Target Recruit Count
- 273
- Registration Number
- NCT07093697
- Locations
- 🇰🇷
Soonchunhyang University Bucheon Hospital, Bucheon, Korea, Republic of
🇰🇷Hallym University Chuncheon Sacred Heart Hospital, Chuncheon, Korea, Republic of
🇰🇷Yeungnam University Medical Center, Daegu, Korea, Republic of
Clinical Trial to Evaluate the Efficacy and Safety of DW1026C1 or DW1026C2
Not Applicable
Completed
- Conditions
- Type 2 Diabetes
- Interventions
- Drug: DW1026C1Drug: DW1026C2Drug: DW1026S
- First Posted Date
- 2025-07-21
- Last Posted Date
- 2025-07-21
- Lead Sponsor
- Daewon Pharmaceutical Co., Ltd.
- Target Recruit Count
- 230
- Registration Number
- NCT07076056
- Locations
- 🇰🇷
Yeouido St. Mary's Hospital The Catholic University, Seoul, Korea, Republic of
Clinical Trial to Evaluate the Pharmacokinetic Characteristics of DW5221 and DW5221-R
- First Posted Date
- 2023-11-28
- Last Posted Date
- 2023-11-28
- Lead Sponsor
- Daewon Pharmaceutical Co., Ltd.
- Target Recruit Count
- 54
- Registration Number
- NCT06147908
- Locations
- 🇰🇷
Chungbuk National University Hospital, Cheongju-si, Korea, Republic of
Clinical Trial to Evaluate the Efficacy and Safety of DW1125 and DW1125A
Phase 3
Completed
- Conditions
- Hypercholesterolemia, Dyslipidemia
- Interventions
- Drug: Ezetimibe/Atorvastatin 10/5 mgDrug: DW1125 placeboDrug: DW1125E placeboDrug: DW1125A placeboDrug: DW1125A-1 placebo
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Daewon Pharmaceutical Co., Ltd.
- Target Recruit Count
- 252
- Registration Number
- NCT05970679
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Clinical Trial to Evaluate the Efficacy and Safety of DWKH
- First Posted Date
- 2023-01-13
- Last Posted Date
- 2023-01-13
- Lead Sponsor
- Daewon Pharmaceutical Co., Ltd.
- Target Recruit Count
- 186
- Registration Number
- NCT05683951
- Locations
- 🇰🇷
Korea University Guro Hospital, Seoul, Korea, Republic of
- Prev
- 1
- 2
- 3
- 4
- 5
- 8
- Next
News
No news found